ECMatrix™-221 E8 Laminin Substrate

Stem Cell Reagent Cat. # CC163-1050UG

FOR RESEARCH USE ONLY.
NOT FOR USE IN DIAGNOSTIC PROCEDURES.
NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Pack size: 1050 µg

Store at 2-8°C



Data Sheet

page 1 of 2

Description

Cardiomyocytes are the cardiac muscle cells that make up the heart and are responsible for generating contractile forces within the heart. Laminin-221 is known to bind to the integrin $\alpha 7X2\beta 1$ which is located on the cell surface of pluripotent stem cells and is known to induce cardiac and skeletal muscle differentiation. Professor Kiyotoshi Sekiguchi's group (Matrixome, Inc.) have produced a recombinant E8 fragment of laminin-221 at large-scale while retaining the full integrin binding activity. ECMatrix $^{\text{TM}}$ -221 E8 Laminin Substrates are recombinant Laminin-221-E8 fragments which bind to integrin $\alpha 7X2\beta 1$ and increases the differentiation of pluripotent stem cells (ES/iPSCs) into functional cardiomyocytes.

Storage and Handling

ECMatrix[™]-221 E8 Laminin Substrates should be stored at 2-8°C. Avoid multiple freeze-thaw cycles and protect from light.

Presentation

1) 6 X 175 µg ECMatrix[™]-221 E8 Laminin Substrate (0.5 mg/mL in PBS). Expressed in CHO-S cells.

Quality Control Testing

- Purity (SDS-Page): > 95%
- Endotoxin Test: ≤ 750 EU/mg
- Mycoplasma Test: Negative
- Sterility Test: Negative
- Integrin Binding Assay (kDa): ≤ 10 nM

Protocol

Precoating Method

- Dilute the 0.5 mg/mL stock solution with sterile PBS to achieve a 2.5 ug/mL working solution.
- Coat dishes with ECMatrix™-221 at 0.25 ug/cm² (for example, for one well of a 6-well plate add 1 mL of the 2.5 ug/mL working solution).
- Incubate for 1 hour at 37°C, 3 hours at room temperate or overnight at 4°C.
- Before use, remove remaining fluid from the coated surface (do not rinse).
- Detach cells into small clumps using Accutase.
- Plate the cells at desired density.

Note: Do not allow the plates to dry, briefly spin down all liquids in the tube before use, avoid repeated freeze-thaw cycles.

References

- Israeli-Rosenberg S, et al. Integrins and integrin-associated proteins in the cardiac myocyte. Circ Res. 2014 Jan 31;114(3):572-586.
- Mummery CL, et al. Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. Cell Mol Life Sci. 2010 Jan;67(2):277-90.
- Ja KP, et al. iPSC-derived human cardiac progenitor cells improve ventricular remodelling via angiogenesis and interstitial networking of infarcted myocardium. J Cell Mol Med. 2016 Feb;20(2):323-32.




Figure 1. Differentiation of human embryonic stem cells into beating cardiomyocytes. Human ES cells differentiated into cardiomyocytes grown on ECMatrix™-221 E8 Laminin Substrates (arrows indicate beating cardiomyocytes).

ECMatrix[™] is a trademark of Merck KGaA Matrigel is a registered trademark of Corning Incorporated

OS SERVICE NEWA

antibodies Multiplex products biotools cell culture enzymes kits proteins/peptides siRNA/cDNA products